glp-1 and gastric bypass Bariatric Surgery Outperforms GLP-1s in Weight Loss Altered glucose metabolism after bariatric

spironolactone is hepatically metabolized Kidney note / NSAIDs plus alcohol plus spironolactone is a high-risk triple combination Menstrual cycle / alcohol raises estrogen levels, which may affect hormonal acne response Safe threshold / no established "safe" dose

Treatment recommendations vary and depend on provider evaluation

The GLP-1/GIP dual-agonist mechanism of tirzepatide can lower blood sugar and reduce appetite within days, while sermorelin's growth hormone elevation typically requires 412 weeks to produce measurable body composition changes

It is often discussed in connection with appetite reduction, slower stomach emptying, and improved blood sugar control